---
id: endophthalmitis_050
category: clinical_syndromes
tags: [endophthalmitis, intravitreal-antibiotics, vancomycin, ceftazidime, post-surgical, eye-infections]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Endophthalmitis: Types and Treatment

**Q:** What are the types of endophthalmitis, their pathogens, and standard treatment with intravitreal antibiotics?

**A:**

**Definition:**
Severe intraocular infection involving vitreous and/or aqueous humor → vision-threatening emergency

**Types:**

**1. Post-Surgical Endophthalmitis (Most Common):**

| **Timing** | **Pathogens** | **Features** |
|------------|---------------|--------------|
| **Acute (<6 weeks)** | • Staph epidermidis (70%)<br>• Staph aureus<br>• Strep species | Most common post-cataract surgery (0.1-0.3%)<br>Onset: 3-7 days post-op |
| **Chronic (>6 weeks)** | • **Propionibacterium acnes** (Cutibacterium)<br>• Coag-negative Staph | Indolent, low-grade inflammation |

**2. Endogenous Endophthalmitis (Hematogenous):**

**Pathogens:**
- **Candida species** (most common endogenous): IVDU, TPN, immunosuppression
- **Bacterial:** Endocarditis (Staph aureus, Strep), Klebsiella (liver abscess), GBS

**Risk factors:** Bacteremia, fungemia, IVDU, immunosuppression

**3. Post-Traumatic:**
- Open globe injury
- Pathogens: Bacillus species, Staph aureus, Strep species, fungi

---

**Diagnosis:**

**Clinical Presentation:**
- **Severe pain**
- **Decreased vision** (rapid progression)
- **Hypopyon** (layered WBCs in anterior chamber)
- **Vitritis** (vitreous haze, loss of red reflex)

**Diagnostic Procedure:**
- **Vitreous tap** (or vitreous biopsy via vitrectomy):
  - Gram stain, culture
  - PCR if available

---

**Treatment: Intravitreal Antibiotics**

**Standard Empiric Regimen:**

**Option 1 (Most Common):**
- **Vancomycin 1 mg/0.1 mL** (Gram-positive)
- **Ceftazidime 2.25 mg/0.1 mL** (Gram-negative)
- **Must use SEPARATE syringes** (precipitation if mixed)

**Option 2:**
- **Vancomycin 1 mg/0.1 mL**
- **Amikacin 0.4 mg/0.1 mL** (alternative to ceftazidime)

**Option 3 (Monotherapy):**
- **Moxifloxacin 0.5 mg/0.1 mL** (broad-spectrum)
- Comparable efficacy to vanc/ceftaz in recent studies

**Key Points:**
- **Intravitreal injection immediately** upon diagnosis
- 100% of bacterial isolates susceptible to vanc + ceftaz (10-year series)
- **Systemic antibiotics:** Controversial, may not improve outcomes (recent 2024 study)

---

**Additional Management:**

**Vitrectomy:**
- Consider for severe cases
- **PPV (pars plana vitrectomy)** allows better vitreous sampling + debridement

**Intravitreal Steroids:**
- Dexamethasone 0.4 mg/0.1 mL (controversial)
- May reduce inflammation but evidence mixed

**Prognosis:**
- **Staph epidermidis:** Better prognosis
- **Staph aureus, Strep, Pseudomonas:** Worse prognosis (aggressive, vision loss common)
- **Candida:** Often requires vitrectomy + systemic antifungals

---

**Mnemonic: "Endophthalmitis = Intravitreal Vanc + Ceftaz, Separate Syringes"**
- **V**ancomycin 1 mg
- **C**eftazidime 2.25 mg
- **S**eparate syringes (they precipitate if mixed)

**Clinical Pearls:**
- **Post-surgical endophthalmitis = ophthalmologic emergency**
- Intravitreal antibiotics are standard of care (NOT just systemic)
- Vancomycin + ceftazidime remains gold standard (despite moxifloxacin monotherapy showing comparable results)
- Always tap vitreous BEFORE injecting antibiotics (if possible)
- **Candida endophthalmitis:** Check for candidemia, start systemic fluconazole/echinocandin + intravitreal amphotericin B

**Media:** None

**Sources:** [PMC 2015 - Postoperative endophthalmitis], [PMC 2015 - Update prevention/treatment], [PMC 2025 - 5-year retrospective cohort], [EyeWiki 2024], [PubMed 2022 - Real-life comparison], [PMC 2019 - Precipitation vanc/ceftaz], [PubMed 2023 - Triple therapy 12-year experience]
